Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06952660 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

StatusRecruiting
PhasePhase 4
SponsorPfizer
Started2025-05-07
View on ClinicalTrials.gov ↗
TIVDAK is used for the treatment of cervical cancer that has come back after chemotherapy. Chemotherapy is a treatment that uses medicines to stop the growth of cancer cells. This is done either by killing the cells or by stopping them from growing. The purpose of this study is to learn about possible side effects of TIVDAK, specially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease. * This study is seeking for participants who: Are willing to take all the required eye tests * Have not received TIVDAK before * Do not have any active eye issues. Participants will receive TIVDAK once every 3 weeks as an infusion that will be injected into the vein. Participants will visit an eye care provider at 3 stages: * before starting the treatment, * before each of the first 9 infusions * then monthly for 3 months after they stop taking TIVDAK. Treatment with TIVDAK will continue until it is not working anymore against the participant's cancer.

Amendment history 2 changes detected by DataLookout

2026-07-23
minor
Trial sites expanded: 93 → 129 locations
2026-04-21
minor
Trial sites expanded: 78 → 93 locations
Trial Details
NCT Number NCT06952660
Lead Sponsor Pfizer
Collaborators: Genmab
Conditions Cervical Cancer
Enrollment 100 participants
Start Date 2025-05-07
Primary Completion 2028-12-13 (estimated)
Study Completion 2028-12-13 (estimated)
Updated on ClinicalTrials.gov 2026-09-04